3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Sarcoma
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma
8
Liposarcoma
8
Hemangiosarcoma
8
Fibrosarcoma
8
Lymphoma, Large B-Cell, Diffuse
7
Sarcoma, Synovial
6
Rhabdomyosarcoma
6
Neurofibrosarcoma
6
Malignant mesenchymal tumor
6
Leukemia
6
Leiomyosarcoma
6
Histiocytoma, Malignant Fibrous
6
Hemangiopericytoma, Malignant
6
Testicular Neoplasms
5
Teratoma
5
Neuroectodermal Tumors, Primitive, Peripheral
5
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Testicular Germ Cell Tumor
4
Ovarian Neoplasms
4
Lymphoma, Non-Hodgkin
4
Endodermal Sinus Tumor
4
Seminoma
3
Neuroblastoma
3
Neoplasm Metastasis
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Carcinoma, Embryonal
3
Interventions
Rituximab
14
pirtobrutinib
6
ibrutinib
4
Vincristine
4
Doxorubicin
4
Prednisone
3
Cytarabine
3
Cyclophosphamide
3
zanubrutinib
2
acalabrutinib
2
Methotrexate
2
Etoposide
2
Bendamustine Hydrochloride
2
venetoclax
1
tositumomab I-131
1
idelalisib
1
ibritumomab tiuxetan
1
etoposide phosphate
1
entecavir
1
cirmtuzumab
1
axicabtagene ciloleucel
1
VAP-cyclo protocol
1
Tenofovir
1
Radiotherapy
1
Melphalan
1
Ifosfamide
1
Gemcitabine
1
Everolimus
1
Drug Therapy
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell
×
Ifosfamide
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled